Thyroid Cancer Trial, Recruiting NCT03483337 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT03483337
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • (Group 1) You have a suspicious spot in the head and neck area that doctors think may be a spread of cancer or a return of cancer
  • (Group 2) You have been confirmed by biopsy to have head and neck cancer or thyroid cancer (certain types) that has come back or spread, located in the head and neck area only
  • (Group 2) You are planning to receive your treatment at Memorial Sloan Kettering (MSK) cancer center

Who may not be able to join:

  • You would need to be put under general anesthesia (fully asleep) to take part in the study
  • You experience claustrophobia (fear of enclosed spaces, such as an MRI machine)
  • You are planning to receive your cancer treatment somewhere other than MSK
  • You have had a known allergic or bad reaction to a gadolinium-based contrast dye (a liquid used to improve MRI scan images)
  • You have a pacemaker (a heart device)
  • You have aneurysm clips (small metal clips placed in the brain or blood vessels)
  • You have any other implanted device or metal in your body that is not safe for MRI scans
  • You are pregnant
  • Due to age or mental status, you are unable to stay still and cooperate during an MRI scan (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amita Dave, PhD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-3184

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 March 2018
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

For group 1: number of patients that have biomarkers that maybe early response to therapy indicators; For group 2: number of patients response to treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov